Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Dalteparin

Alison P. Thornton  1 , Mayur Parmar  1
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Dalteparin

Alison P. Thornton et al.
Free Books & Documents

Excerpt

Dalteparin sodium is a low molecular weight heparin (LMWH) medication used to manage venous thromboembolism (VTE), deep vein thrombosis (DVT), and ischemic complications of unstable angina and non-Q-wave myocardial infarction. The medication is derived from unfractionated heparin to form LMWH and is commonly administered as a subcutaneous injection. Symptoms of overdose necessitate urgent medical attention, with protamine sulfate as an antidote. Routine complete blood counts and stool occult blood tests are recommended during treatment with dalteparin, and patients with renal insufficiency require additional monitoring. Concomitant use of medications that affect coagulation may pose similar risks as other heparins.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Alison Thornton declares no relevant financial relationships with ineligible companies.

Disclosure: Mayur Parmar declares no relevant financial relationships with ineligible companies.

References

    1. Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016 Jan;41(1):15-31. - PMC - PubMed
    1. Hao C, Sun M, Wang H, Zhang L, Wang W. Low molecular weight heparins and their clinical applications. Prog Mol Biol Transl Sci. 2019;163:21-39. - PubMed
    1. van Bergen EDP, Huisman A, Welsing PMJ, de Winter MA, Rookmaaker MB, Kaasjager HAH, Nijkeuter M. Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring. Neth J Med. 2019 Dec;77(10):360-365. - PubMed
    1. Dunn CJ, Jarvis B. Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs. 2000 Jul;60(1):203-37. - PubMed
    1. Kovacs MJ, Wells PS, Anderson DR, Lazo-Langner A, Kearon C, Bates SM, Blostein M, Kahn SR, Schulman S, Sabri E, Solymoss S, Ramsay T, Yeo E, Rodger MA, PERIOP2 Investigators Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ. 2021 Jun 09;373:n1205. - PMC - PubMed

Publication types

LinkOut - more resources